Free Trial
NASDAQ:CODX

Co-Diagnostics (CODX) Stock Price, News & Analysis

Co-Diagnostics logo
$0.31 +0.00 (+0.29%)
Closing price 04:00 PM Eastern
Extended Trading
$0.31 0.00 (-0.58%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Co-Diagnostics Stock (NASDAQ:CODX)

Key Stats

Today's Range
$0.31
$0.31
50-Day Range
$0.25
$0.34
52-Week Range
$0.23
$1.40
Volume
114,283 shs
Average Volume
1.03 million shs
Market Capitalization
$11.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Co-Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

CODX MarketRank™: 

Co-Diagnostics scored higher than 85% of companies evaluated by MarketBeat, and ranked 175th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Co-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    Co-Diagnostics has a consensus price target of $5.50, representing about 1,675.3% upside from its current price of $0.31.

  • Amount of Analyst Coverage

    Co-Diagnostics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Co-Diagnostics' stock forecast and price target.
  • Earnings Growth

    Earnings for Co-Diagnostics are expected to grow in the coming year, from ($1.22) to ($1.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Co-Diagnostics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Co-Diagnostics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Co-Diagnostics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Co-Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    1.33% of the outstanding shares of Co-Diagnostics have been sold short.
  • Short Interest Ratio / Days to Cover

    Co-Diagnostics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Co-Diagnostics has recently decreased by 14.32%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Co-Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Co-Diagnostics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.33% of the outstanding shares of Co-Diagnostics have been sold short.
  • Short Interest Ratio / Days to Cover

    Co-Diagnostics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Co-Diagnostics has recently decreased by 14.32%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 3 people have searched for CODX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Co-Diagnostics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.40% of the stock of Co-Diagnostics is held by insiders.

  • Percentage Held by Institutions

    Only 14.99% of the stock of Co-Diagnostics is held by institutions.

  • Read more about Co-Diagnostics' insider trading history.
Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CODX Stock News Headlines

2013 Bitcoin miner reveals his trading system (free)
While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day.tc pixel
Co-Diagnostics CODX Earnings Call Transcript
See More Headlines

CODX Stock Analysis - Frequently Asked Questions

Co-Diagnostics' stock was trading at $0.75 at the beginning of 2025. Since then, CODX stock has decreased by 58.7% and is now trading at $0.3098.

Co-Diagnostics, Inc. (NASDAQ:CODX) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. The firm had revenue of $0.16 million for the quarter, compared to analysts' expectations of $0.30 million. Co-Diagnostics had a negative net margin of 3,588.33% and a negative trailing twelve-month return on equity of 69.49%.
Read the conference call transcript
.

Co-Diagnostics (CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

Co-Diagnostics' top institutional shareholders include Jane Street Group LLC (0.50%).
View institutional ownership trends
.

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

Last Earnings
8/14/2025
Today
9/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:CODX
CIK
1692415
Fax
N/A
Employees
100
Year Founded
2013

Price Target and Rating

High Price Target
$10.00
Low Price Target
$1.00
Potential Upside/Downside
+1,675.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.64 million
Net Margins
-3,588.33%
Pretax Margin
-3,584.55%
Return on Equity
-69.49%
Return on Assets
-60.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.12
Quick Ratio
3.83

Sales & Book Value

Annual Sales
$3.91 million
Price / Sales
3.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.70 per share
Price / Book
0.18

Miscellaneous

Outstanding Shares
38,520,000
Free Float
35,288,000
Market Cap
$11.93 million
Optionable
Optionable
Beta
0.78

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CODX) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners